Mini review · 13 Feb 2026
Conference abstractPublished 17 Oct 2016
Chronic lymphocytic leukemia: Risk factors and complications
Menoufia University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Definition: Chronic lymphocytic leukemia (CLL) results from an acquired (not present at birth mutation (change)) to the DNA of a single marrow cell that develops into a lymphocyte. Scientists do not yet understand what causes this change. Once the marrow cell undergoes the leukemic change, it multiplies into many cells. CLL cells grow and survive better than normal cells; over time, they crowd out normal cells. The result is the uncontrolled growth of CLL cells in the marrow, leading to an increase in the number of CLL cells in the blood. The leukemic cells that accumulate in the marrow in people with CLL do not prevent normal blood cell production as extensively as is the case with acute lymphoblastic leukemia. Risk Factors: First-degree relatives of patients with CLL are three to four times more likely to develop CLL than people who do not have first-degree relatives with the disease. Old age is second risk factor of CLL development. Sign and symptoms: Early, some people with CLL do not have any symptoms. The disease may be suspected because of abnormal results from blood tests that were ordered either as part of an annual physical or a medical examination for an unrelated condition. An unexplained elevated white blood cell (lymphocyte) count is the most common finding that leads a doctor to consider a CLL diagnosis. Diagnosis: The diagnosis of CLL is usually evident from the results of blood cell counts and an examination of blood cells. A bone marrow aspiration and biopsy generally are not needed to make a diagnosis of CLL provided the red blood cells and platelets are normal. âÂ?Â?Immunopheno typingâÂ? (or flow cytometry) of lymphocytes is an important process used to diagnose CLL, and other types of leukemia and lymphoma, by comparing the cancer cells to normal immune cells. Staging for CLL helps doctors to both assess how the disease is expected to progress over time and also to develop a treatment plan. Complications: CLL or CLL Treatment: Infections are a common complication for people with CLL. Anemia (low numbers of red blood cells) is a common side effect of chemotherapy. In about 3 to 5 percent of people with CLL, the disease transforms into an aggressive lymphoma (Richter Transformation) because of a change in the characteristics of the CLL cells. About 15 percent of people with CLL develop prolymphocytic leukemia. Some people with CLL produce a type of antibody that works against their own cells (Autoimmune Hemolytic Anemia). People with CLL have a higher risk than the general population of developing a second cancer. Conclusion: People with CLL need regular medical follow-up after they have completed treatment. It is important to assess the full effect of therapy as well as to identify any return of progressive disease that may require additional therapy.
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Hematology & Thromboembolic Diseases.
Opinion · 25 Dec 2025
Clinical Patterns and Systemic Implications of Thromboembolism
Opinion · 25 Dec 2025
Integrating Clinical Risk and Preventive Care in Thromboembolism Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hematology & Thromboembolic Diseases
- SubjectHaematology
- BylineArticles whose byline prints “Olfat M Hendy”
